travel
medicin
infecti
diseas
journal
homepag
wwwelseviercomlocatetmaid
remdesivir
possibl
therapeut
option
editor
recent
review
articl
multipl
prevent
measur
propos
middl
east
respiratori
syndrom
coronaviru
merscov
sinc
wit
emerg
three
coronavirus
signific
impact
sever
acut
respiratori
syndrom
coronaviru
sarscov
merscov
caus
agent
emerg
wuhan
china
decemb
accord
world
health
organ
global
number
confirm
case
februari
howev
recommend
therapi
cov
remdesivir
develop
code
broadspectrum
antivir
agent
medic
experiment
drug
licens
approv
time
write
articl
synthes
develop
gilead
scienc
treatment
ebola
viru
infect
monophosphoramid
prodrug
adenosin
analog
remdesivir
metabol
activ
form
obscur
viral
rna
polymeras
evad
proofread
viral
exonucleas
caus
decreas
viral
rna
product
antivir
mechan
remdesivir
delay
chain
cessat
nascent
viral
rna
remdesivir
show
antivir
activ
multipl
variant
ebola
viru
cellbas
assay
well
rhesu
monkey
model
ebola
viru
diseas
remdesivir
given
compassionateus
basi
british
nurs
initi
surviv
ebola
viru
diseas
relaps
nine
month
later
meningoenceph
random
control
trial
ebola
viru
diseas
therapeut
particip
receiv
one
three
monoclon
antibodi
zmapp
remdesivir
howev
studi
stop
interim
analysi
found
individu
receiv
greater
surviv
rate
either
zmapp
remdesivir
invitro
studi
show
remdesivir
inhibit
coronavirus
sarscov
merscov
replic
invitro
test
util
epitheli
cell
cultur
primari
human
airway
remdesivir
effect
batcov
prepandem
batcov
circul
contemporari
humancov
primari
human
lung
cell
one
studi
show
remdesiv
interferon
beta
superior
lopinavir
ritonavir
interferon
beta
vitro
merscov
mous
model
emerg
etiolog
agent
need
effect
antivir
agent
abl
halt
current
outbreak
suggest
remdesivir
might
option
therapi
patient
case
report
remdisivir
reatment
start
intraven
day
patient
given
broadspectrum
anticov
activ
remdesivir
demonstr
preclin
studi
random
control
doubl
blind
clinic
trial
plan
evalu
efficaci
safeti
remdesivir
hospit
patient
mild
moder
respiratori
diseas
trial
alreadi
involv
hospit
adult
patient
particip
random
either
placebo
remdesivir
arm
remdesivir
given
mg
load
dose
day
follow
mg
iv
oncedaili
day
primari
outcom
defin
time
clinic
recoveri
ttcr
day
ttcr
defin
time
hour
initi
studi
treatment
activ
placebo
normal
fever
respiratori
rate
oxygen
satur
allevi
cough
sustain
least
hour
anoth
ongo
phase
random
doubleblind
placebocontrol
multicent
studi
evalu
efficaci
safeti
remdesivir
hospit
adult
patient
sever
respiratori
diseas
clinic
impact
remdesivir
remain
unknown
scientist
wait
patient
final
result
ongo
trial
author
conflict
interest
